MEN1 and gastrin-producing neuroendocrine tumor: These MEN1 mutations are more frequent in gastrinomas (37%), VIPomas (44%), and glucagonomas (67%), while less frequent in insulinomas and nonfunctioning PanNETs (8%) [54,55].